A Phase 1 study of PYC-003 in healthy and ADPKD participants
Recruiting Phase 1 NCT06714006
Study Description
A First-in-Human Study to Evaluate the Safety and Tolerability of an Investigational Drug (PYC-003) in Healthy Participants and Participants with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Study Details
- Registry ID:
- NCT06714006
- Conditions:
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Phase:
- Phase 1
- Target Enrollment:
- 166 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (12 sites)
-
Linear Clinical Research
Joondalup, Western Australia, Australia -
Linear Clinical Research
Nedlands, Western Australia, Australia -
Sunshine Hospital, Western Centre for Health Research and Education, Level 3, 176-190 Furlong Road
Saint Albans, Victoria, Australia -
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia -
Doherty Clinical Trials (Satellite site for Liverpool Hospital), Level 2, 2 St Andrews Place
East Melbourne, Victoria, Australia -
Liverpool Hospital, Clinic G-Reception 133, Level 1, Clinical Building, Burnside Drive
Liverpool, New South Wales, Australia -
Westmead Hospital, Clinical Research Unit, Level 6, B Wing/Building, Hawkesbury Road
Westmead, New South Wales, Australia -
Sydney Adventist Hospital
Wahroonga, New South Wales, Australia -
Concord Repatriation General Hospital
Concord, New South Wales, Australia -
Mater Hospital Brisbane
South Brisbane, Queensland, Australia -
South Coast Renal, Brockway House, Level 1, Suite 8, 82-86 Queen Street,
Southport, Gold Coast, Australia -
Pacific Clinical Research Network Auckland
Takapuna, Auckland, New Zealand
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.org.